<div id="readability-page-1"><div> <div> , /PRNewswire/ -- miraDry, Inc., a global leader in non-surgical underarm sweat and odor reduction, today announced 55% year-over-year growth in patient spend and a 43% increase in total treatments in the first quarter of 2026 compared to first quarter 2025. This growth significantly outpaces the broader medical aesthetic energy-based device (EBD) market, which grew just 4% over the same period. The performance is validated by third-party data from Guidepoint Qsight, leveraging near real-time, transaction-level point-of-sale data feeds from aesthetic practices to track patient spend, treatment volume, market trends, and demographic shifts with a high degree of accuracy. Together, the increase in both patient spend and treatment volume signals strong underlying patient demand, positioning miraDry as a clear outlier in a legacy aesthetic EBD category experiencing modest growth. &#34;This is a clear shift toward treatments that help patients feel better, not just look better,&#34; said Kelly Holbin, Head of Consumable Sales, North America at miraDry. &#34;Practices leaning into this are seeing broader patient reach and consistent demand with miraDry.&#34; miraDry continues to expand beyond its traditional patient base. Patients over age 35 increased by 8% year-over-year and now represent nearly half of all miraDry patients, reflecting growing demand among individuals experiencing increased sweat and odor through midlife. Approximately 70% of women in perimenopause report increased body odor, yet only 9% discuss it, highlighting a large and underserved patient population. &#34;We're seeing growing provider interest in miraDry as a way to differentiate and get ahead of the wellness shift,&#34; said Larry Lewis, Vice President of Sales, North America at miraDry. &#34;Practices that position it within a broader wellness offering are winning new patients and driving sustainable growth.&#34; As part of its commitment to education and awareness, miraDry kicks off its annual Odor Awareness Week on Monday, April 20, 2026. A featured webinar will take place on Thursday, April 23 at 9:00 a.m. PT / 12:00 p.m. ET, led by Chris Callewaert, also known as &#34;Dr. Armpit.&#34; The session will explore the science of odor, emerging patient trends, and practical approaches for providers. Register here: https://us06web.zoom.us/webinar/register/WN_yA-XxF0oR5mqQjAICmlL9Q#/registration For more information, visit www.miradry.com. About miraDry® miraDry is an innovative, FDA-cleared treatment that provides a long-lasting solution for excessive underarm sweat, odor, and hair. Safe, immediate, and non-surgical, miraDry reduces sweat glands and hair follicles in the underarms, delivering lasting results and high patient satisfaction. More than 500,000 patients have been treated globally. SOURCE miraDry <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIwJk5ld3NJdGVtSWQ9TEEzODc0NCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjAxNTUwUFJfTkVXU19VU1BSX19fX19MQTM4NzQ0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIwJk5ld3NJdGVtSWQ9TEEzODc0NCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjAxNTUwUFJfTkVXU19VU1BSX19fX19MQTM4NzQ0"/></div> </div></div>

CS精准医

MIRA

miraDry, Inc. reported a 55% year-over-year growth in patient spend and a 43% increase in total treatments in Q1 2026, significantly outpacing the 4% growth of the broader aesthetic energy-based device market. This growth indicates strong patient demand, particularly among individuals over 35, who now make up nearly half of miraDry's patients. The company is launching Odor Awareness Week on April 20, 2026, featuring a webinar on odor science and patient trends. miraDry offers a non-surgical solution for excessive underarm sweat and odor, with over 500,000 patients treated globally.

prnewswire

Geratherm Medical AG

Mira Pharmaceuticals

ChinaAMC CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE Health Care ETF Initiating Fund

Health Care Select Sector SPDR

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bear 3X

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

iShares US Pharma

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

iShares Global Healthcare

E Fund CSI 300 Health Care ETF

VG Health

15:50 ETmiraDry® Reports 55% Growth in Patient Spend, Significantly Outpacing Aesthetic Energy-Based Device Market, and Kicks Off Odor Awareness Week